Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Ioana Agache, Claudio Rocha, Jessica Beltran, Yang Song, Margarita Posso, Ivan Solà, Pablo Alonso-Coello, Cezmi Akdis, Mubeccel Akdis, Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika MäkeläIrene Hernández Martín, Parameswaran Nair, Liam O’Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae-Sim Park, Luis Pérez de Llano, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Carlos Canelo-Aybar, Oscar Palomares, Marek Jutel

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Originalspråkengelska
TidskriftAllergy : European journal of allergy and clinical immunology
Volym75
Utgåva5
Sidor (från-till)1043-1057
Antal sidor15
ISSN0105-4538
DOI
StatusPublicerad - maj 2020
MoE-publikationstypA1 Tidskriftsartikel-refererad

Vetenskapsgrenar

  • 3121 Inre medicin

Citera det här